Nuance Pharma
Nuance Pharma is a Shanghai-based specialty biopharmaceutical company founded in 2014 that develops and commercializes first-in-class therapies in respiratory disease, emergency cardiac care, iron deficiency anemia, and pain management across China and Asia Pacific, operating both an integrated commercial platform with 5 marketed products and a late-stage pipeline of 4 clinical assets.
- Company typePrivate
- Founded2014
- HeadquartersShanghai, China
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nuance Pharma does
Nuance Pharma (also operating as Nuance Biotech, legal name 优锐医药科技（上海）有限公司) is a Shanghai-headquartered specialty care biopharmaceutical company founded in 2014 by Mark Lotter. The company operates a "dual-wheel model" that pairs self-sustaining commercial operations with late-stage clinical pipeline development across four therapeutic areas: respiratory disease (COPD, neonatal respiratory distress syndrome, and allergic rhinitis), emergency cardiac care, iron deficiency anemia, and post-operative pain management. End customers are primarily hospitals, healthcare providers, and patients across China and Asia Pacific markets.
The company's commercial portfolio includes NIFEREX (iron polysaccharide complex capsules), ISOKET (isosorbide dinitrate injection and spray), ELANTAN (isosorbide mononitrate sustained-release capsules), and OLPRINONE (olprinone hydrochloride) for heart failure — the latter three acquired through the 2021 Sino Health acquisition — alongside the recently launched Bentrio nasal spray for allergic rhinitis. The late-stage clinical pipeline features four differentiated assets: Ohtuvayre (ensifentrine), a first-in-class selective dual inhibitor of PDE3 and PDE4 licensed from Verona Pharma, representing the first novel inhaled mechanism for COPD maintenance treatment in over 20 years; AeroFact, a non-invasive nasal surfactant delivery system for neonatal RDS combining bovine lung surfactant with Aerogen's patented PDAP aerosol technology; NTM-001 (ketorolac), a non-opioid alcohol-free IV infusion for post-operative pain licensed from Neumentum; and Actair, a sublingual immunotherapy tablet for house dust mite allergy licensed from Stallergenes Greer.
Nuance generates revenue through a mix of direct product sales in China and Asia Pacific, upfront licensing payments and milestone receipts from global partners (including a US$219 million Verona Pharma strategic collaboration), and ongoing royalties. Distribution is anchored by a strategic cooperation agreement with Shanghai Pharmaceutical Co., Ltd. covering 30,000+ medical institution terminals across 17 Chinese provinces, complemented by direct field sales operations with 200+ employees, a DKSH partnership for Hong Kong and Macau, and wholly-owned subsidiaries in Shanghai, Beijing, Hong Kong, Zhuhai, Chengdu, and Cologne, Germany. Investors include CBC Group (lead Series D), Matrix Partners China, RTW Investments, HBM Healthcare Investments, Konruns Pharmaceutical, and state-backed funds Guoxin Guotong and Jiashan Guotou.
Nuance Pharma firmographics
Firmographics- Name
- Nuance Pharma
- Legal name
- 优锐医药科技（上海）有限公司
- Website
- https://nuancepharma.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Nuance Pharma is a Shanghai-based specialty biopharmaceutical company founded in 2014 that develops and commercializes first-in-class therapies in respiratory disease, emergency cardiac care, iron deficiency anemia, and pain management across China and Asia Pacific, operating both an integrated commercial platform with 5 marketed products and a late-stage pipeline of 4 clinical assets.
- Ownership category
- akta.pro rank
Nuance Pharma industry classification
Industry- Product category
- Specialty Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industry
- Respiratory & Allergy Pharmaceuticals (HLAIAAAH)
Keywords
Where Nuance Pharma is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices6 records
Markets served
Nuance Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Product Sales: Commercialization of pharmaceutical products across respiratory, emergency care, iron deficiency anemia, and pain management in China and Asia Pacific markets. Products include NIFEREX (iron polysaccharide complex), ISOKET (isosorbide dinitrate), ELANTAN (isosorbide mononitrate), and OLPRINONE.
- Licensing and Milestone Payments: Strategic collaborations with global pharmaceutical companies generate upfront payments, development milestones, and commercialization royalties. Examples include $219M strategic collaboration with Verona Pharma for ensifentrine, $53M deal with Neumentum for NTM-001.
- Milestone Payments: One-time milestone payments upon regulatory approvals. Received $1 million milestone payment from partner Altamira Therapeutics upon NMPA approval of Bentrio nasal spray in China.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels4 records
Nuance Pharma product offering
Product offeringCore offering
Nuance Pharma is a specialty care biopharmaceutical company that develops, in-licenses, and commercializes therapies across four therapeutic areas: respiratory diseases (COPD, neonatal RDS, allergic rhinitis), emergency care (cardiovascular conditions), iron deficiency anemia, and post-operative pain management. The company operates a dual-wheel model combining self-sustaining commercial operations for 5 marketed products with a late-stage clinical pipeline of 4 candidates, serving patients and healthcare providers in China and Asia Pacific.
Product overview
Nuance Pharma operates as a specialty care biopharma company with both commercialized products and a late-stage clinical pipeline. The portfolio spans four therapeutic areas: Respiratory (Ohtuvayre™ for COPD, Bentrio™ nasal spray, Actair® in development), Emergency Care (ISOKET®, ELANTAN®, OPRINONE for cardiovascular conditions), Iron Deficiency Anemia (NIFEREX®), and Pain Management (NTM-001 for post-operative pain). The company also has AeroFact™ in development for neonatal respiratory distress syndrome. Products are distributed across China mainland, Hong Kong, Macau, Taiwan, and other Asia Pacific territories under various licensing and distribution agreements with global partners including Verona Pharma, Aerogen Pharma, Altamira Therapeutics, Stallergenes Greer, and Neumentum.
Differentiator
Problem solved
Functional benefit
Products and services
- Ohtuvayre (ensifentrine) First-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Delivered via standard jet nebulizer for COPD maintenance treatment in adult patients. Licensed from Verona Pharma for Greater China.
- AeroFact Nasally inhaled surfactant combining bovine lung surfactant (Alveofact) with Aerogen's next-generation PDAP delivery technology for non-invasive treatment of neonatal respiratory distress syndrome (RDS) in preterm infants. Licensed from Aerogen Pharma for Greater China.
- Bentrio (倍愈朗) Drug-free nasal spray that forms a protective gel layer on nasal mucosa to prevent contact of allergens and viruses with cells, binding particles and aiding their discharge. Indicated for allergic rhinitis and upper respiratory tract viral infection protection. Licensed from Altamira Therapeutics for China mainland, Hong Kong, Macau, and Korea.
- NTM-001 (Ketorolac) Novel alcohol-free formulation of ketorolac in ready-to-use pre-mixed bag for continuous 24-hour IV infusion for post-operative pain treatment without opioid risks. Licensed from Neumentum for China.
- Actair Sublingual immunotherapy (SLIT) tablet for house dust mite (HDM)-induced allergic rhinitis and asthma. Licensed from Stallergenes Greer for development and commercialization in China.
- NIFEREX Iron polysaccharide complex capsules for treatment of iron deficiency anemia. Trademarked across multiple Asia Pacific territories; acquired by Nuance in 2019.
- ISOKET (异舒吉) Isosorbide dinitrate injection and spray for treatment of acute heart failure, angina, and myocardial infarction in Mainland China.
- ELANTAN (异乐定) Isosorbide mononitrate sustained-release capsules for treatment of heart failure, coronary heart disease, and angina.
- OPRINONE (奥普利农) Olprinone hydrochloride injection for treatment of heart failure.
Quantifiable outcome
- Ohtuvayre met primary endpoint in ENHANCE-CHINA Phase 3 trial with statistically significant lung function improvement
- +3 more outcomes
Companies that use Nuance Pharma
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles1 record
Nuance Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Nuance Pharma partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and important.
- Stallergenes GreercoreExclusive long-term partnership for development and commercialization of Actair (house dust mite SLIT tablet) in China. Actair addresses allergic rhinitis and asthma, expanding Nuance's allergy portfolio.
- DKSHimportantPartnership for Bentrio nasal spray launch in Hong Kong and Macau markets.
- Chinese Organization for Rare Disorders (CORD)importantCollaboration for rare disease R&D advancement, clinical research, registry development, and patient education. Focus on neonatal respiratory distress syndrome.
- Shanghai Pharmaceutical Co., Ltd.coreStrategic cooperation agreement for commercial distribution. Shanghai Pharma operates distribution network covering 30,000+ medical institution terminals across 17 provinces and cities in China.
- Aerogen PharmacoreExclusive partnership to develop and commercialize AeroFact for treatment of neonatal respiratory distress syndrome (RDS) in Greater China. AeroFact combines bovine lung surfactant with Aerogen's PDAP delivery technology for non-invasive treatment.
- Verona Pharmacore$219 million strategic collaboration to develop and commercialize ensifentrine (Ohtuvayre) in Greater China. Nuance paid $40 million upfront including $25M cash and $15M equity. Includes development, regulatory, and sales milestones plus royalties.
Scale indicators12 records
Recent moves7 records
Expansion highlights6 records
Nuance Pharma competitors and assessment
Company assessmentDirect peers
- Everest Medicines: Shanghai-based clinical-stage biopharma that licenses and develops innovative therapies for the Asia-Pacific region. Closely mirrors Nuance's in-licensing-plus-regional-commercialization model across respiratory, anti-infectives and cardio/renal indications.
- HUTCHMED (China) Limited: Hong Kong- and Shanghai-based biopharma commercializing innovative oncology and specialty therapies in China and globally. Comparable as a China-focused innovative drug developer with both in-licensed and proprietary assets, late-stage pipeline, and dual US/HK listing.
- Cstone Pharmaceuticals: China- and US-based biopharma developing and commercializing immuno-oncology and specialty therapies through a similar in-license-plus-regional-development model. Directly comparable as a China-focused specialty biopharma at a similar stage.
- BeiGene: Global oncology-focused biopharma headquartered in Beijing with major China commercial operations. Comparable as a large-scale Chinese biopharma running China clinical development of innovative therapies and commercializing through broad hospital channels.
- Innovent Biologics: China-headquartered biopharmaceutical company developing and commercializing innovative medicines, primarily oncology but expanding into other specialty areas. Comparable as a Chinese specialty biopharma with both proprietary R&D and in-licensed assets and a HK-listed commercial platform.
- Zai Lab: China-headquartered specialty biopharma commercializing in-licensed global therapies across oncology and specialty areas. Highly comparable in business model: in-licensing Western assets, running China clinical trials, and commercializing through a regional hospital-focused platform — just at a larger scale with a public listing.
- Akeso, Inc. China-based biopharmaceutical company developing innovative biologics across oncology and immunology. Comparable as a Chinese specialty biopharma combining proprietary R&D with in-licensing, with both commercial products and late-stage pipeline.
Broad incumbents
- Shanghai Pharmaceuticals Holding: China's largest pharmaceutical distributor and a major domestic pharma manufacturer. Comparable as Nuance's strategic distribution partner (covering 30,000+ medical institutions) and as a broader incumbent operating across prescription drugs, distribution and healthcare services in China.
- AstraZeneca: Global biopharma leader with a major China commercial presence and dominant respiratory franchise (Symbicort, Breztri, Trixeo). Comparable as both a broader incumbent and former employer of Nuance's leadership — directly competitive in the China COPD market where Ohtuvayre will launch.
- Sino Biopharmaceutical: Hong Kong-listed Chinese pharmaceutical conglomerate with broad therapeutic coverage including respiratory and cardiovascular products. Comparable as a broad incumbent in the same therapeutic areas (respiratory, cardiology, oncology) with established hospital sales force across China.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Nuance Pharma social profiles
Digital presenceNuance Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nuance Pharma leadership team
Management profileNumber of profiles
Profiles3 records
Nuance Pharma subsidiaries and ownership
Company hierarchySubsidiaries3 records
Nuance Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nuance Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nuance Pharma
What does Nuance Pharma do?
Nuance Pharma is a specialty care biopharmaceutical company that develops, in-licenses, and commercializes therapies across four therapeutic areas: respiratory diseases (COPD, neonatal RDS, allergic rhinitis), emergency care (cardiovascular conditions), iron deficiency anemia, and post-operative pain management. The company operates a dual-wheel model combining self-sustaining commercial operations for 5 marketed products with a late-stage clinical pipeline of 4 candidates, serving patients and healthcare providers in China and Asia Pacific.
Is Nuance Pharma a public or private company?
Nuance Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nuance Pharma founded?
Nuance Pharma was founded in 2014. It employs 11 to 50 people.
Where is Nuance Pharma based?
Nuance Pharma is headquartered in Shanghai, China, in the Asia region.
How does Nuance Pharma make money?
Three revenue lines are on record. Product Sales are the primary driver. The others are licensing and Milestone Payments and milestone Payments.
Who are Nuance Pharma's main competitors?
Direct peers on record are Everest Medicines, HUTCHMED (China) Limited, Cstone Pharmaceuticals, BeiGene, Innovent Biologics, Zai Lab and Akeso, Inc.. Broad incumbents are Shanghai Pharmaceuticals Holding, AstraZeneca and Sino Biopharmaceutical.
Does Nuance Pharma have an API?
No public API is recorded for Nuance Pharma.
What industry is Nuance Pharma in?
Nuance Pharma's product category is Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.